VICE PRESIDENT OF CHEMISTRY, SEATTLE GENETICS

DR. PETER SENTER

Monday, May 14, 2018

6:00 pm

-

7:00 pm

Monoclonal antibodies have played a major role in the treatment of cancer, with approved, active drugs such as Herceptin, Erbitux, Avastin and Rituxan for a wide range of therapeutic applications.  Our focus has been on developing next-generation cancer therapeutics by using monoclonal antibodies for the selective delivery of high potency chemotherapeutic drugs.  This presentation will give a background on targeted drug delivery, an overview of how Adcetris was discovered and developed, and some reflections on where this area of science is headed.

Back To All Superheroes of Science
Give To Education.